Brii Biosciences presents Phase IIb data for hepatitis B drug BRII-179
AI Summary- Brii Biosciences presented follow-up data from two Phase IIb studies of BRII-179.
- BRII-179 was evaluated as part of a simultaneous triple-combination therapy involving elebsir.
- The data were presented at the American Association for the Study of Liver Diseases annual meeting.